10 December 2015
Principal Philip Lucas and Senior Associate Ailyn Tydde are acting for Gleneagle Gold Limited on the acquisition of Zelda Therapeutics. Zelda is in the process of launching Phase 2 clinical trials using medicinal cannabis formulations in Canada, Spain and Israel.
Please click here to read ASX Market Announcement.